MARKET

DMRA

DMRA

DAMORA THERAPEUT
NASDAQ
25.51
-3.18
-11.08%
After Hours: 26.69 +1.18 +4.63% 19:26 03/10 EDT
OPEN
27.99
PREV CLOSE
28.69
HIGH
29.22
LOW
25.00
VOLUME
216.72K
TURNOVER
--
52 WEEK HIGH
38.33
52 WEEK LOW
2.010
MARKET CAP
1.54B
P/E (TTM)
-2.1248
1D
5D
1M
3M
1Y
5Y
1D
Galecto announces name change to Damora Therapeutics
TipRanks · 1d ago
Galecto Changes Name To Damora Therapeutics, Symbol To DMRA, Effective March 10
Benzinga · 1d ago
GALECTO INC - CHANGES NAME TO DAMORA THERAPEUTICS; TO TRADE AS "DMRA" ON NASDAQ MARCH 10, 2026
Reuters · 1d ago
GALECTO INC - DAMORA TO SUBMIT IND OR CTA FOR DMR-001 IN MID-2026; PROOF-OF-CONCEPT DATASETS EXPECTED MID-2027
Reuters · 1d ago
Weekly Report: what happened at GLTO last week (0302-0306)?
Weekly Report · 2d ago
Galecto reports inducement grants under Nasdaq listing rule
TipRanks · 6d ago
Galecto Grants Inducement Stock Options to New Hires Under Nasdaq Rule 5635(c)(4)
Reuters · 6d ago
GALECTO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
More
About DMRA
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Webull offers Galecto Inc stock information, including NASDAQ: DMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMRA stock methods without spending real money on the virtual paper trading platform.